Physician profile
Mitchell R Weinstein
NPI 1447270475
$11,066.93
in general payments reported to CMS, 2019-2025
23 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,652 · 2020: $1,410 · 2021: $1,723 · 2022: $1,928 · 2023: $1,474 · 2024: $1,242 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,306 · Education: $47.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,305.72 |
| Education | $47.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,377.50 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $2,330.52 | 2019-2025 | Dovato, Apretude, Rukobia |
| Janssen Biotech, INC. | $981.14 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $940.98 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Melinta Therapeutics, LLC | $722.96 | 2019-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Abbvie INC. | $479.98 | 2019-2025 | Avycaz, Mavyret |
| Napo Pharmaceuticals INC | $428.29 | 2019-2025 | Mytesi |
| Becton, Dickinson and Company | $426.67 | 2022 | |
| Paratek Pharmaceuticals, INC. | $302.28 | 2019-2025 | Nuzyra |
| Theratechnologies INC. | $236.28 | 2019-2025 | Trogarzo, Egrifta |
| Shionogi INC | $216.78 | 2019-2025 | Fetroja |
| Insmed, INC. | $112.35 | 2025 | Arikayce |
| Astellas Pharma US INC | $95.54 | 2019-2023 | Cresemba, Xtandi |
| Nabriva Therapeutics, Plc | $64.99 | 2020-2021 | |
| Janssen Products, Lp | $60.48 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $59.12 | 2022-2023 | Symtuza |
| Mayne Pharma Commercial LLC | $53.24 | 2019-2022 | |
| Tetraphase Pharmaceuticals, INC. | $41.83 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $35.76 | 2019 | |
| Allergan, INC. | $35.28 | 2019-2020 | |
| Exact Sciences Corporation | $25.94 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.65 | 2019 | |
| Ferring Pharmaceuticals INC. | $19.37 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.